Table of Contents Author Guidelines Submit a Manuscript
Journal of Biomedicine and Biotechnology
Volume 2010, Article ID 690438, 17 pages
http://dx.doi.org/10.1155/2010/690438
Review Article

Immunomodulatory Effects of dsRNA and Its Potential as Vaccine Adjuvant

1Department of Digestive Diseases, Naval General Hospital, 6 Fucheng Rd., Beijing 100048, China
2Department of Hepatobiliary Surgery, Naval General Hospital, Beijing 100048, China
3Department of Pathology, Naval General Hospital, Beijing 100048, China
4Sherman Oaks, CA 91411, USA

Received 31 December 2009; Accepted 9 May 2010

Academic Editor: Zhengguo Xiao

Copyright © 2010 Bo Jin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. T. Seya, M. Matsumoto, T. Ebihara, and H. Oshiumi, “Functional evolution of the TICAM-1 pathway for extrinsic RNA sensing,” Immunological Reviews, vol. 227, no. 1, pp. 44–53, 2009. View at Publisher · View at Google Scholar · View at PubMed
  2. H. J. Warshakoon, J. D. Hood, and J. D. Hood, “Potential adjuvantic properties of innate immune stimuli,” Human Vaccines, vol. 5, no. 6, pp. 381–394, 2009. View at Google Scholar
  3. K. J. Ish II, S. Koyama, A. Nakagawa, C. Coban, and S. Akira, “Host innate immune receptors and beyond: making sense of microbial infections,” Cell Host and Microbe, vol. 3, no. 6, pp. 352–363, 2008. View at Publisher · View at Google Scholar · View at PubMed
  4. H. Kumar, T. Kawai, and S. Akira, “Pathogen recognition in the innate immune response,” Biochemical Journal, vol. 420, no. 1, pp. 1–16, 2009. View at Publisher · View at Google Scholar · View at PubMed
  5. S. Bauer, T. Müller, and S. Hamm, “Pattern recognition by Toll-like receptors,” Advances in Experimental Medicine and Biology, vol. 653, pp. 15–34, 2009. View at Google Scholar
  6. R. Medzhitov, P. Preston-Hurlburt, and C. A. Janeway Jr., “A human homologue of the Drosophila toll protein signals activation of adaptive immunity,” Nature, vol. 388, no. 6640, pp. 394–397, 1997. View at Publisher · View at Google Scholar · View at PubMed
  7. M. Yoneyama, M. Kikuchi, and M. Kikuchi, “The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses,” Nature Immunology, vol. 5, no. 7, pp. 730–737, 2004. View at Publisher · View at Google Scholar · View at PubMed
  8. M. Yoneyama and T. Fujita, “Function of RIG-I-like receptors in antiviral innate immunity,” Journal of Biological Chemistry, vol. 282, no. 21, pp. 15315–15318, 2007. View at Publisher · View at Google Scholar · View at PubMed
  9. J. H. Fritz, R. L. Ferrero, D. J. Philpott, and S. E. Girardin, “Nod-like proteins in immunity, inflammation and disease,” Nature Immunology, vol. 7, no. 12, pp. 1250–1257, 2006. View at Publisher · View at Google Scholar · View at PubMed
  10. J. P.-Y. Ting, S. B. Willingham, and D. T. Bergstralh, “NLRs at the intersection of cell death and immunity,” Nature Reviews Immunology, vol. 8, no. 5, pp. 372–379, 2008. View at Publisher · View at Google Scholar · View at PubMed
  11. H. Kumar, T. Kawai, and S. Akira, “Toll-like receptors and innate immunity,” Biochemical and Biophysical Research Communications, vol. 388, no. 4, pp. 621–625, 2009. View at Publisher · View at Google Scholar · View at PubMed
  12. P. Ranjan, J. B. Bowzard, J. W. Schwerzmann, V. Jeisy-Scott, T. Fujita, and S. Sambhara, “Cytoplasmic nucleic acid sensors in antiviral immunity,” Trends in Molecular Medicine, vol. 15, no. 8, pp. 359–368, 2009. View at Publisher · View at Google Scholar · View at PubMed
  13. X. Li, C. Lu, M. Stewart, H. Xu, R. K. Strong, T. Igumenova, and P. Li, “Structural basis of double-stranded RNA recognition by the RIG-I like receptor MDA5,” Archives of Biochemistry and Biophysics, vol. 488, no. 1, pp. 23–33, 2009. View at Publisher · View at Google Scholar · View at PubMed
  14. L. Franchi, T. Eigenbrod, R. Muñoz-Planillo, and G. Nuñez, “The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis,” Nature Immunology, vol. 10, no. 3, pp. 241–247, 2009. View at Publisher · View at Google Scholar · View at PubMed
  15. T. Kawai and S. Akira, “Innate immune recognition of viral infection,” Nature Immunology, vol. 7, no. 2, pp. 131–137, 2006. View at Publisher · View at Google Scholar · View at PubMed
  16. M. S. Jin and J.-O. Lee, “Structures of TLR-ligand complexes,” Current Opinion in Immunology, vol. 20, no. 4, pp. 414–419, 2008. View at Publisher · View at Google Scholar · View at PubMed
  17. M. S. Jin and J.-O. Lee, “Structures of the toll-like receptor family and its ligand complexes,” Immunity, vol. 29, no. 2, pp. 182–191, 2008. View at Publisher · View at Google Scholar · View at PubMed
  18. N. Matsushima, T. Tanaka, P. Enkhbayar, T. Mikami, M. Taga, K. Yamada, and Y. Kuroki, “Comparative sequence analysis of leucine-rich repeats (LRRs) within vertebrate toll-like receptors,” BMC Genomics, vol. 8, article 124, 2007. View at Publisher · View at Google Scholar · View at PubMed
  19. J. Bella, K. L. Hindle, P. A. McEwan, and S. C. Lovell, “The leucine-rich repeat structure,” Cellular and Molecular Life Sciences, vol. 65, no. 15, pp. 2307–2333, 2008. View at Publisher · View at Google Scholar · View at PubMed
  20. J. Choe, M. S. Kelker, and I. A. Wilson, “Crystal structure of human toll-like receptor 3 (TLR3) ectodomain,” Science, vol. 309, no. 5734, pp. 581–585, 2005. View at Publisher · View at Google Scholar · View at PubMed
  21. J. K. Bell, J. Askins, P. R. Hall, D. R. Davies, and D. M. Segal, “The dsRNA binding site of human Toll-like receptor 3,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 23, pp. 8792–8797, 2006. View at Publisher · View at Google Scholar · View at PubMed
  22. L. Liu, I. Botos, Y. Wang, J. N. Leonard, J. Shiloach, D. M. Segal, and D. R. Davies, “Structural basis of toll-like receptor 3 signaling with double-stranded RNA,” Science, vol. 320, no. 5874, pp. 379–381, 2008. View at Publisher · View at Google Scholar · View at PubMed
  23. J. N. Leonard, R. Ghirlando, J. Askins, J. K. Bell, D. H. Margulies, D. R. Davies, and D. M. Segal, “The TLR3 signaling complex forms by cooperative receptor dimerization,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 1, pp. 258–263, 2008. View at Publisher · View at Google Scholar · View at PubMed
  24. K. Fukuda, T. Watanabe, and T. Watanabe, “Modulation of double-stranded RNA recognition by the N-terminal histidine-rich region of the human toll-like receptor 3,” Journal of Biological Chemistry, vol. 283, no. 33, pp. 22787–22794, 2008. View at Publisher · View at Google Scholar · View at PubMed
  25. E. Vercammen, J. Staal, and R. Beyaert, “Sensing of viral infection and activation of innate immunity by toll-like receptor 3,” Clinical Microbiology Reviews, vol. 21, no. 1, pp. 13–25, 2008. View at Publisher · View at Google Scholar · View at PubMed
  26. H. Oshiumi, M. Matsumoto, K. Funami, T. Akazawa, and T. Seya, “TICAM-1, an adaptor molecule that participates in Toll-like receptor 3-mediated interferon-β induction,” Nature Immunology, vol. 4, no. 2, pp. 161–167, 2003. View at Publisher · View at Google Scholar · View at PubMed
  27. G. C. Sen and S. N. Sarkar, “Transcriptional signaling by double-stranded RNA: role of TLR3,” Cytokine and Growth Factor Reviews, vol. 16, no. 1, pp. 1–14, 2005. View at Publisher · View at Google Scholar · View at PubMed
  28. M. Matsumoto, K. Funami, and K. Funami, “Subcellular localization of toll-like receptor 3 in human dendritic cells,” Journal of Immunology, vol. 171, no. 6, pp. 3154–3162, 2003. View at Google Scholar
  29. M. Matsumoto, S. Kikkawa, M. Kohase, K. Miyake, and T. Seya, “Establishment of a monoclonal antibody against human Toll-like receptor 3 that blocks double-stranded RNA-mediated signaling,” Biochemical and Biophysical Research Communications, vol. 293, no. 5, pp. 1364–1369, 2002. View at Publisher · View at Google Scholar · View at PubMed
  30. H.-K. Lee, S. Dunzendorfer, K. Soldau, and P. S. Tobias, “Double-stranded RNA-mediated TLR3 activation is enhanced by CD14,” Immunity, vol. 24, no. 2, pp. 153–163, 2006. View at Publisher · View at Google Scholar · View at PubMed
  31. S. Sato, M. Sugiyama, M. Yamamoto, Y. Watanabe, T. Kawai, K. Takeda, and S. Akira, “Toll/IL-1 receptor domain-containing adaptor inducing IFN-β (TRIF) associates with TNF receptor-associated factor 6 and TANK-binding kinase 1, and activates two distinct transcription factors, NF-κB and IFN-regulatory factor-3, in the toll-like receptor signaling,” Journal of Immunology, vol. 171, no. 8, pp. 4304–4310, 2003. View at Google Scholar
  32. M. Matsumoto and T. Seya, “TLR3: interferon induction by double-stranded RNA including poly(I:C),” Advanced Drug Delivery Reviews, vol. 60, no. 7, pp. 805–812, 2008. View at Publisher · View at Google Scholar · View at PubMed
  33. N. Cusson-Hermance, S. Khurana, T. H. Lee, K. A. Fitzgerald, and M. A. Kelliher, “Rip1 mediates the trif-dependent Toll-like receptor 3- and 4-induced NF-κB activation but does not contribute to interferon regulatory factor 3 activation,” Journal of Biological Chemistry, vol. 280, no. 44, pp. 36560–36566, 2005. View at Publisher · View at Google Scholar · View at PubMed
  34. M. Sasai, H. Oshiumi, M. Matsumoto, N. Inoue, F. Fujita, M. Nakanishi, and T. Seya, “Cutting edge: NF-κB-activating kinase-associated protein 1 participates in TLR3/Toll-IL-1 homology domain-containing adapter molecule-1-mediated IFN regulatory factor 3 activation,” Journal of Immunology, vol. 174, no. 1, pp. 27–30, 2005. View at Google Scholar
  35. H. Häcker, V. Redecke, and V. Redecke, “Specificity in Toll-like receptor signalling through distinct effector functions of TRAF3 and TRAF6,” Nature, vol. 439, no. 7073, pp. 204–207, 2006. View at Publisher · View at Google Scholar · View at PubMed
  36. S. N. Sarkar, K. L. Peters, C. P. Elco, S. Sakamoto, S. Pal, and G. C. Sen, “Novel roles of TLR3 tyrosine phosphorylation and PI3 kinase in double-stranded RNA signaling,” Nature Structural and Molecular Biology, vol. 11, no. 11, pp. 1060–1067, 2004. View at Publisher · View at Google Scholar · View at PubMed
  37. S. N. Sarkar, C. P. Elco, K. L. Peters, S. Chattopadhyay, and G. C. Sen, “Two tyrosine residues of toll-like receptor 3 trigger different steps of NF-κB activation,” Journal of Biological Chemistry, vol. 282, no. 6, pp. 3423–3427, 2007. View at Publisher · View at Google Scholar · View at PubMed
  38. I. B. Johnsen, T. T. Nguyen, and T. T. Nguyen, “Toll-like receptor 3 associates with c-Src tyrosine kinase on endosomes to initiate antiviral signaling,” EMBO Journal, vol. 25, no. 14, pp. 3335–3346, 2006. View at Publisher · View at Google Scholar · View at PubMed
  39. W. J. Kaiser and M. K. Offermann, “Apoptosis induced by the toll-like receptor adaptor TRIF is dependent on its receptor interacting protein homotypic interaction motif,” Journal of Immunology, vol. 174, no. 8, pp. 4942–4952, 2005. View at Google Scholar
  40. O. Takeuchi and S. Akira, “MDA5/RIG-I and virus recognition,” Current Opinion in Immunology, vol. 20, no. 1, pp. 17–22, 2008. View at Publisher · View at Google Scholar · View at PubMed
  41. L. Unterholzner and A. G. Bowie, “The interplay between viruses and innate immune signaling: recent insights and therapeutic opportunities,” Biochemical Pharmacology, vol. 75, no. 3, pp. 589–602, 2008. View at Publisher · View at Google Scholar · View at PubMed
  42. T. Saito, R. Hirai, and R. Hirai, “Regulation of innate antiviral defenses through a shared repressor domain in RIG-1 and LGP2,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 2, pp. 582–587, 2007. View at Publisher · View at Google Scholar · View at PubMed
  43. A. Baum and A. Garcia-Sastre, “Induction of type I interferon by RNA viruses: cellular receptors and their substrates,” Amino Acids, vol. 38, no. 5, pp. 1283–1299, 2010. View at Google Scholar
  44. S. Cui, K. Eisenächer, and K. Eisenächer, “The C-terminal regulatory domain is the RNA 5-triphosphate sensor of RIG-I,” Molecular Cell, vol. 29, no. 2, pp. 169–179, 2008. View at Publisher · View at Google Scholar · View at PubMed
  45. K. Takahasi, H. Kumeta, and H. Kumeta, “Solution structures of cytosolic RNA sensor MDA5 and LGP2 C-terminal domains: identification of the RNA recognition loop in RIG-I-like receptors,” Journal of Biological Chemistry, vol. 284, no. 26, pp. 17465–17474, 2009. View at Publisher · View at Google Scholar · View at PubMed
  46. D. A. Pippig, J. C. Hellmuth, and J. C. Hellmuth, “The regulatory domain of the RIG-I family ATPase LGP2 senses double-stranded RNA,” Nucleic Acids Research, vol. 37, no. 6, pp. 2014–2025, 2009. View at Publisher · View at Google Scholar · View at PubMed
  47. S. Myong, S. Cui, and S. Cui, “Cytosolic viral sensor RIG-I is a 5-triphosphate-dependent translocase on double-stranded RNA,” Science, vol. 323, no. 5917, pp. 1070–1074, 2009. View at Publisher · View at Google Scholar · View at PubMed
  48. D. Bamming and C. M. Horvath, “Regulation of signal transduction by enzymatically inactive antiviral RNA helicase proteins MDA5, RIG-I, and LGP2,” Journal of Biological Chemistry, vol. 284, no. 15, pp. 9700–9712, 2009. View at Publisher · View at Google Scholar · View at PubMed
  49. A. Schmidt, T. Schwerd, and T. Schwerd, “5-triphosphate RNA requires base-paired structures to activate antiviral signaling via RIG-I,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 29, pp. 12067–12072, 2009. View at Publisher · View at Google Scholar · View at PubMed
  50. M. Yoneyama, M. Kikuchi, and M. Kikuchi, “Shared and unique functions of the DExD/H-box helicases RIG-I, MDA5, and LGP2 in antiviral innate immunity,” Journal of Immunology, vol. 175, no. 5, pp. 2851–2858, 2005. View at Google Scholar
  51. F. Diao, S. Li, and S. Li, “Negative regulation of MDA5- but not RIG-I-mediated innate antiviral signaling by the dihydroxyacetone kinase,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 28, pp. 11706–11711, 2007. View at Publisher · View at Google Scholar · View at PubMed
  52. V. Hornung, J. Ellegast, and J. Ellegast, “5-triphosphate RNA is the ligand for RIG-I,” Science, vol. 314, no. 5801, pp. 994–997, 2006. View at Publisher · View at Google Scholar · View at PubMed
  53. A. Pichlmair, O. Schulz, C. P. Tan, T. I. Näslund, P. Liljeström, F. Weber, and C. Reis E Sousa, “RIG-I-mediated antiviral responses to single-stranded RNA bearing 5-phosphates,” Science, vol. 314, no. 5801, pp. 997–1001, 2006. View at Publisher · View at Google Scholar · View at PubMed
  54. H. Kato, O. Takeuchi, and O. Takeuchi, “Length-dependent recognition of double-stranded ribonucleic acids by retinoic acid-inducible gene-I and melanoma differentiation-associated gene 5,” Journal of Experimental Medicine, vol. 205, no. 7, pp. 1601–1610, 2008. View at Publisher · View at Google Scholar · View at PubMed
  55. M. Schlee, E. Hartmann, C. Coch, V. Wimmenauer, M. Janke, W. Barchet, and G. Hartmann, “Approaching the RNA ligand for RIG-I?” Immunological Reviews, vol. 227, no. 1, pp. 66–74, 2009. View at Publisher · View at Google Scholar · View at PubMed
  56. L. Gitlin, W. Barchet, and W. Barchet, “Essential role of mda-5 in type I IFN responses to polyriboinosinic: polyribocytidylic acid and encephalomyocarditis picornavirus,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 22, pp. 8459–8464, 2006. View at Publisher · View at Google Scholar · View at PubMed
  57. R. B. Seth, L. Sun, C.-K. Ea, and Z. J. Chen, “Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-κB and IRF3,” Cell, vol. 122, no. 5, pp. 669–682, 2005. View at Publisher · View at Google Scholar · View at PubMed
  58. S. K. Saha, E. M. Pietras, and E. M. Pietras, “Regulation of antiviral responses by a direct and specific interaction between TRAF3 and Cardif,” EMBO Journal, vol. 25, no. 14, pp. 3257–3263, 2006. View at Publisher · View at Google Scholar · View at PubMed
  59. M. Baril, M.-E. Racine, F. Penin, and D. Lamarre, “MAVS dimer is a crucial signaling component of innate immunity and the target of hepatitis C virus NS3/4A protease,” Journal of Virology, vol. 83, no. 3, pp. 1299–1311, 2009. View at Publisher · View at Google Scholar · View at PubMed
  60. E. D. Tang and C.-Y. Wang, “MAVS self-association mediates antiviral innate immune signaling,” Journal of Virology, vol. 83, no. 8, pp. 3420–3428, 2009. View at Publisher · View at Google Scholar · View at PubMed
  61. M. Yoneyama and T. Fujita, “RNA recognition and signal transduction by RIG-I-like receptors,” Immunological Reviews, vol. 227, no. 1, pp. 54–65, 2009. View at Publisher · View at Google Scholar · View at PubMed
  62. P. Nakhaei, P. Genin, A. Civas, and J. Hiscott, “RIG-I-like receptors: sensing and responding to RNA virus infection,” Seminars in Immunology, vol. 21, no. 4, pp. 215–222, 2009. View at Publisher · View at Google Scholar · View at PubMed
  63. L.-G. Xu, Y.-Y. Wang, K.-J. Han, L.-Y. Li, Z. Zhai, and H.-B. Shu, “VISA is an adapter protein required for virus-triggered IFN-β signaling,” Molecular Cell, vol. 19, no. 6, pp. 727–740, 2005. View at Publisher · View at Google Scholar · View at PubMed
  64. R. Yoshida, G. Takaesu, and G. Takaesu, “TRAF6 and MEKK1 play a pivotal role in the RIG-I-like helicase antiviral pathway,” Journal of Biological Chemistry, vol. 283, no. 52, pp. 36211–36220, 2008. View at Publisher · View at Google Scholar · View at PubMed
  65. S. S. Mikkelsen, S. B. Jensen, and S. B. Jensen, “RIG-I-mediated activation of p38 MAPK is essential for viral induction of interferon and activation of dendritic cells: dependence on TRAF2 and TAK1,” Journal of Biological Chemistry, vol. 284, no. 16, pp. 10774–10782, 2009. View at Publisher · View at Google Scholar · View at PubMed
  66. M.-C. Michallet, E. Meylan, and E. Meylan, “TRADD protein is an essential component of the RIG-like helicase antiviral pathway,” Immunity, vol. 28, no. 5, pp. 651–661, 2008. View at Publisher · View at Google Scholar · View at PubMed
  67. B. Zhong, Y. Yang, and Y. Yang, “The adaptor protein MITA links virus-sensing receptors to IRF3 transcription factor activation,” Immunity, vol. 29, no. 4, pp. 538–550, 2008. View at Publisher · View at Google Scholar · View at PubMed
  68. H. Ishikawa and G. N. Barber, “STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling,” Nature, vol. 455, no. 7213, pp. 674–678, 2008. View at Publisher · View at Google Scholar · View at PubMed
  69. L. Jin, P. M. Waterman, K. R. Jonscher, C. M. Short, N. A. Reisdorph, and J. C. Cambier, “MPYS, a novel membrane tetraspanner, is associated with major histocompatibility complex class II and mediates transduction of apoptotic signals,” Molecular and Cellular Biology, vol. 28, no. 16, pp. 5014–5026, 2008. View at Publisher · View at Google Scholar · View at PubMed
  70. H. Poeck, M. Bscheider, and M. Bscheider, “Recognition of RNA virus by RIG-I results in activation of CARD9 and inflammasome signaling for interleukin 1β production,” Nature Immunology, vol. 11, no. 1, pp. 63–69, 2010. View at Publisher · View at Google Scholar · View at PubMed
  71. F. Martinon, A. Mayor, and J. Tschopp, “The inflammasomes: guardians of the body,” Annual Review of Immunology, vol. 27, pp. 229–265, 2009. View at Publisher · View at Google Scholar · View at PubMed
  72. L. Franchi, N. Warner, K. Viani, and G. Nuñez, “Function of Nod-like receptors in microbial recognition and host defense,” Immunological Reviews, vol. 227, no. 1, pp. 106–128, 2009. View at Publisher · View at Google Scholar · View at PubMed
  73. D. D. Leipe, E. V. Koonin, and L. Aravind, “STAND, a class of P-loop NTPases including animal and plant regulators of programmed cell death: multiple, complex domain architectures, unusual phyletic patterns, and evolution by horizontal gene transfer,” Journal of Molecular Biology, vol. 343, no. 1, pp. 1–28, 2004. View at Publisher · View at Google Scholar · View at PubMed
  74. J. P.-Y. Ting, R. C. Lovering, and R. C. Lovering, “The NLR gene family: a standard nomenclature,” Immunity, vol. 28, no. 3, pp. 285–287, 2008. View at Publisher · View at Google Scholar · View at PubMed
  75. T.-D. Kanneganti, M. Body-Malapel, and M. Body-Malapel, “Critical role for Cryopyrin/Nalp3 in activation of caspase-1 in response to viral infection and double-stranded RNA,” Journal of Biological Chemistry, vol. 281, no. 48, pp. 36560–36568, 2006. View at Publisher · View at Google Scholar · View at PubMed
  76. T.-D. Kanneganti, N. Özören, and N. Özören, “Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3,” Nature, vol. 440, no. 7081, pp. 233–236, 2006. View at Publisher · View at Google Scholar · View at PubMed
  77. I. C. Allen, M. A. Scull, and M. A. Scull, “The NLRP3 inflammasome mediates in vivo innate immunity to influenza a virus through recognition of viral RNA,” Immunity, vol. 30, no. 4, pp. 556–565, 2009. View at Publisher · View at Google Scholar · View at PubMed
  78. P. G. Thomas, P. Dash, and P. Dash , “The Intracellular Sensor NLRP3 Mediates Key Innate and Healing Responses to Influenza A Virus via the Regulation of Caspase-1,” Immunity, vol. 30, no. 4, pp. 566–575, 2009. View at Publisher · View at Google Scholar · View at PubMed
  79. D. A. Muruve, V. Pétrilli, and V. Pétrilli, “The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response,” Nature, vol. 452, no. 7183, pp. 103–107, 2008. View at Publisher · View at Google Scholar · View at PubMed
  80. J. H. Pedra, S. L. Cassel, and F. S. Sutterwala, “Sensing pathogens and danger signals by the inflammasome,” Current Opinion in Immunology, vol. 21, no. 1, pp. 10–16, 2009. View at Publisher · View at Google Scholar · View at PubMed
  81. S. L. Cassel, S. Joly, and F. S. Sutterwala, “The NLRP3 inflammasome: a sensor of immune danger signals,” Seminars in Immunology, vol. 21, no. 4, pp. 194–198, 2009. View at Publisher · View at Google Scholar · View at PubMed
  82. L. Agostini, F. Martinon, K. Burns, M. F. McDermott, P. N. Hawkins, and J. Tschopp, “NALP3 forms an IL-1 β-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder,” Immunity, vol. 20, no. 3, pp. 319–325, 2004. View at Publisher · View at Google Scholar
  83. M. Razmara, S. M. Srinivasula, and S. M. Srinivasula, “CARD-8 protein, a new CARD family member that regulates caspase-1 activation and apoptosis,” Journal of Biological Chemistry, vol. 277, no. 16, pp. 13952–13958, 2002. View at Publisher · View at Google Scholar · View at PubMed
  84. R. N. Wagner, M. Proell, T. A. Kufer, and R. Schwarzenbacher, “Evaluation of Nod-like receptor (NLR) effector domain interactions,” PLoS ONE, vol. 4, no. 4, article e4931, 2009. View at Publisher · View at Google Scholar · View at PubMed
  85. C. Dostert, V. Pétrilli, R. Van Bruggen, C. Steele, B. T. Mossman, and J. Tschopp, “Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica,” Science, vol. 320, no. 5876, pp. 674–677, 2008. View at Publisher · View at Google Scholar · View at PubMed
  86. A. J. Fay, X. Qian, Y. N. Jan, and L. Y. Jan, “SK channels mediate NADPH oxidase-independent reactive oxygen species production and apoptosis in granulocyte,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 46, pp. 17548–17553, 2006. View at Publisher · View at Google Scholar · View at PubMed
  87. J. Li and J. Yuan, “Caspases in apoptosis and beyond,” Oncogene, vol. 27, no. 48, pp. 6194–6206, 2008. View at Publisher · View at Google Scholar · View at PubMed
  88. M. Lamkanfi and V. M. Dixit, “Inflammasomes: guardians of cytosolic sanctity,” Immunological Reviews, vol. 227, no. 1, pp. 95–105, 2009. View at Publisher · View at Google Scholar · View at PubMed
  89. C. A. Dinarello, “Immunological and inflammatory functions of the interleukin-1 family,” Annual Review of Immunology, vol. 27, pp. 519–550, 2009. View at Publisher · View at Google Scholar · View at PubMed
  90. T. Ichinohe, H. K. Lee, Y. Ogura, R. Flavell, and A. Iwasaki, “Inflammasome recognition of influenza virus is essential for adaptive immune responses,” Journal of Experimental Medicine, vol. 206, no. 1, pp. 79–87, 2009. View at Publisher · View at Google Scholar · View at PubMed
  91. O. Joffre, M. A. Nolte, R. Spörri, and C. R. E. Sousa, “Inflammatory signals in dendritic cell activation and the induction of adaptive immunity,” Immunological Reviews, vol. 227, no. 1, pp. 234–247, 2009. View at Publisher · View at Google Scholar · View at PubMed
  92. M. P. Longhi, C. Trumpfheller, and C. Trumpfheller, “Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant,” Journal of Experimental Medicine, vol. 206, no. 7, pp. 1589–1602, 2009. View at Publisher · View at Google Scholar · View at PubMed
  93. N. W. Palm and R. Medzhitov, “Pattern recognition receptors and control of adaptive immunity,” Immunological Reviews, vol. 227, no. 1, pp. 221–233, 2009. View at Publisher · View at Google Scholar · View at PubMed
  94. M. Schröder and A. G. Bowie, “TLR3 in antiviral immunity: key player or bystander?” Trends in Immunology, vol. 26, no. 9, pp. 462–468, 2005. View at Publisher · View at Google Scholar · View at PubMed
  95. S. M. Santini, C. Lapenta, L. Santodonato, G. D'Agostino, F. Belardelli, and M. Ferrantini, “IFN-alpha in the generation of dendritic cells for cancer immunotherapy,” Handbook of Experimental Pharmacology, no. 188, pp. 295–317, 2009. View at Google Scholar
  96. T. Avril, M. De Tayrac, C. Leberre, and V. Quillien, “Not all polyriboinosinic-polyribocytidylic acids (Poly I:C) are equivalent for inducing maturation of dendritic cells: Implication for α-type-1 polarized DCs,” Journal of Immunotherapy, vol. 32, no. 4, pp. 353–362, 2009. View at Publisher · View at Google Scholar · View at PubMed
  97. I. Tirapu, B. Giquel, L. Alexopoulou, S. Uematsu, R. Flavell, S. Akira, and S. S. Diebold, “PolyI:C-induced reduction in uptake of soluble antigen is independent of dendritic cell activation,” International Immunology, vol. 21, no. 7, pp. 871–879, 2009. View at Publisher · View at Google Scholar · View at PubMed
  98. S. Manicassamy and B. Pulendran, “Modulation of adaptive immunity with Toll-like receptors,” Seminars in Immunology, vol. 21, no. 4, pp. 185–193, 2009. View at Publisher · View at Google Scholar · View at PubMed
  99. J. E. Smith-Garvin, G. A. Koretzky, and M. S. Jordan, “T cell activation,” Annual Review of Immunology, vol. 27, pp. 591–619, 2009. View at Publisher · View at Google Scholar · View at PubMed
  100. J. Taylor-Papadimitriou, J. M. Burchell, K. T. Papazisis, and H. R. Bohnenkamp, “Synergism of Toll-like receptor-induced interleukin-12p70 secretion by monocyte-derived dendritic cells is mediated through p38 MAPK and lowers the threshold of T-helper cell type 1 responses,” Cellular Immunology, vol. 247, no. 2, pp. 72–84, 2007. View at Google Scholar
  101. M. C. Lebre, J. C. Antons, P. Kalinski et al., “Double-stranded RNA-exposed human keratinocytes promote Th1 responses by inducing a Type-1 polarized phenotype in dendritic cells: role of keratinocyte-derived tumor necrosis factor alpha, type I interferons, and interleukin-18,” The Journal of Investigative Dermatology, vol. 120, no. 6, pp. 990–997, 2003. View at Google Scholar
  102. A. Le Bon and D. F. Tough, “Type I interferon as a stimulus for cross-priming,” Cytokine and Growth Factor Reviews, vol. 19, no. 1, pp. 33–40, 2008. View at Publisher · View at Google Scholar · View at PubMed
  103. K. E. Kehoe, M. A. Brown, and F. Imani, “Double-stranded RNA regulates IL-4 expression,” Journal of Immunology, vol. 167, no. 5, pp. 2496–2501, 2001. View at Google Scholar
  104. C. Stahl-Hennig, M. Eisenblätter, and M. Eisenblätter, “Synthetic double-stranded RNAs are adjuvants for the induction of t helper 1 and humoral immune responses to human papillomavirus in rhesus macaques,” PLoS Pathogens, vol. 5, no. 4, article e1000373, 2009. View at Publisher · View at Google Scholar · View at PubMed
  105. B. Jin, R. Y. Wang, Q. Qiu, F. Sugauchi, T. Grandinetti, H. J. Alter, and J. W.-K. Shih, “Induction of potent cellular immune response in mice by hepatitis C virus NS3 protein with double-stranded RNA,” Immunology, vol. 122, no. 1, pp. 15–27, 2007. View at Publisher · View at Google Scholar · View at PubMed
  106. S. G. Jeon, S.-Y. Oh, and S.-Y. Oh, “TH2 and TH1 lung inflammation induced by airway allergen sensitization with low and high doses of double-stranded RNA,” Journal of Allergy and Clinical Immunology, vol. 120, no. 4, pp. 803–812, 2007. View at Publisher · View at Google Scholar · View at PubMed
  107. O. Schulz, S. S. Diebold, and S. S. Diebold, “Toll-like receptor 3 promotes cross-priming to virus-infected cells,” Nature, vol. 433, no. 7028, pp. 887–892, 2005. View at Publisher · View at Google Scholar · View at PubMed
  108. H. Kumar, S. Koyama, K. J. Ish II, T. Kawai, and S. Akira, “Cutting edge: cooperation of IPS-1- and TRIF-dependent pathways in poly IC-enhanced antibody production and cytotoxic T cell responses,” Journal of Immunology, vol. 180, no. 2, pp. 683–687, 2008. View at Google Scholar
  109. A. Le Bon, V. Durand, and V. Durand, “Direct stimulation of T cells by type I IFN enhances the CD8+ T cell response during cross-priming,” Journal of Immunology, vol. 176, no. 8, pp. 4682–4689, 2006. View at Google Scholar
  110. M.-L. Lin, Y. Zhan, J. A. Villadangos, and A. M. Lew, “The cell biology of cross-presentation and the role of dendritic cell subsets,” Immunology and Cell Biology, vol. 86, no. 4, pp. 353–362, 2008. View at Publisher · View at Google Scholar · View at PubMed
  111. M. L. Salem, C. M. Diaz-Montero, S. A. EL-Naggar, Y. Chen, O. Moussa, and D. J. Cole, “The TLR3 agonist poly(I:C) targets CD8+ T cells and augments their antigen-specific responses upon their adoptive transfer into naïve recipient mice,” Vaccine, vol. 27, no. 4, pp. 549–557, 2009. View at Publisher · View at Google Scholar · View at PubMed
  112. F. Ghiringhelli, L. Apetoh, and L. Apetoh, “Activation of the NLRP3 inflammasome in dendritic cells induces IL-1 β-dependent adaptive immunity against tumors,” Nature Medicine, vol. 15, no. 10, pp. 1170–1178, 2009. View at Publisher · View at Google Scholar · View at PubMed
  113. L. E. Harrington, R. D. Hatton, P. R. Mangan, H. Turner, T. L. Murphy, K. M. Murphy, and C. T. Weaver, “Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages,” Nature Immunology, vol. 6, no. 11, pp. 1123–1132, 2005. View at Publisher · View at Google Scholar · View at PubMed
  114. H. Park, Z. Li, and Z. Li, “A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17,” Nature Immunology, vol. 6, no. 11, pp. 1133–1141, 2005. View at Publisher · View at Google Scholar · View at PubMed
  115. P. Miossec, T. Korn, and V. K. Kuchroo, “Interleukin-17 and type 17 helper T cells,” New England Journal of Medicine, vol. 361, no. 9, pp. 888–898, 2009. View at Publisher · View at Google Scholar · View at PubMed
  116. S. Romagnani, “Human Th17 cells,” Arthritis Research and Therapy, vol. 10, no. 2, article 206, 2008. View at Publisher · View at Google Scholar · View at PubMed
  117. P. R. Mangan, L. E. Harrington, and L. E. Harrington, “Transforming growth factor-β induces development of the T H17 lineage,” Nature, vol. 441, no. 7090, pp. 231–234, 2006. View at Publisher · View at Google Scholar · View at PubMed
  118. M. Veldhoen, R. J. Hocking, C. J. Atkins, R. M. Locksley, and B. Stockinger, “TGFβ in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells,” Immunity, vol. 24, no. 2, pp. 179–189, 2006. View at Publisher · View at Google Scholar · View at PubMed
  119. S. Aggarwal, N. Ghilardi, M.-H. Xie, F. J. De Sauvage, and A. L. Gurney, “Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17,” Journal of Biological Chemistry, vol. 278, no. 3, pp. 1910–1914, 2003. View at Publisher · View at Google Scholar · View at PubMed
  120. I. I. Ivanov, B. S. McKenzie, and B. S. McKenzie, “The orphan nuclear receptor RORγt directs the differentiation program of proinflammatory IL-17+ T helper cells,” Cell, vol. 126, no. 6, pp. 1121–1133, 2006. View at Publisher · View at Google Scholar · View at PubMed
  121. L. Zhou, J. E. Lopes, and J. E. Lopes, “TGF-β-induced Foxp3 inhibits TH17 cell differentiation by antagonizing RORγt function,” Nature, vol. 453, no. 7192, pp. 236–240, 2008. View at Publisher · View at Google Scholar · View at PubMed
  122. N. Morishima, I. Mizoguchi, K. Takeda, J. Mizuguchi, and T. Yoshimoto, “TGF-β is necessary for induction of IL-23R and Th17 differentiation by IL-6 and IL-23,” Biochemical and Biophysical Research Communications, vol. 386, no. 1, pp. 105–110, 2009. View at Publisher · View at Google Scholar · View at PubMed
  123. F. Fossiez, O. Djossou, and O. Djossou, “T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines,” Journal of Experimental Medicine, vol. 183, no. 6, pp. 2593–2603, 1996. View at Publisher · View at Google Scholar
  124. T. Seya and M. Matsumoto, “The extrinsic RNA-sensing pathway for adjuvant immunotherapy of cancer,” Cancer Immunology, Immunotherapy, vol. 58, no. 8, pp. 1175–1184, 2009. View at Publisher · View at Google Scholar · View at PubMed
  125. S. Goriely, M. F. Neurath, and M. Goldman, “How microorganisms tip the balance between interleukin-12 family members,” Nature Reviews Immunology, vol. 8, no. 1, pp. 81–86, 2008. View at Publisher · View at Google Scholar · View at PubMed
  126. T. Korn, E. Bettelli, M. Oukka, and V. K. Kuchroo, “IL-17 and Th17 cells,” Annual Review of Immunology, vol. 27, pp. 485–517, 2009. View at Publisher · View at Google Scholar · View at PubMed
  127. B. Guo, E. Y. Chang, and G. Cheng, “The type I IFN induction pathway constrains Th17-mediated autoimmune inflammation in mice,” Journal of Clinical Investigation, vol. 118, no. 5, pp. 1680–1690, 2008. View at Publisher · View at Google Scholar · View at PubMed
  128. C. K. Holm, C. C. Petersen, M. Hvid, L. Petersen, S. R. Paludan, B. Deleuran, and M. Hokland, “TLR3 ligand polyinosinic: polycytidylic acid induces IL-17A and IL-21 synthesis in human Th cells,” Journal of Immunology, vol. 183, no. 7, pp. 4422–4431, 2009. View at Publisher · View at Google Scholar · View at PubMed
  129. J. Tanaka, N. Watanabe, M. Kido et al., “Human TSLP and TLR3 ligands promote differentiation of Th17 cells with a central memory phenotype under Th2-polarizing conditions,” Clinical and Experimental Allergy, vol. 39, no. 1, pp. 89–100, 2009. View at Google Scholar
  130. J. E. Christensen and A. R. Thomsen, “Co-ordinating innate and adaptive immunity to viral infection: mobility is the key,” APMIS, vol. 117, no. 5-6, pp. 338–355, 2009. View at Publisher · View at Google Scholar · View at PubMed
  131. B. Salaun, M. Greutert, and P. Romero, “Toll-like receptor 3 is necessary for dsRNA adjuvant effects,” Vaccine, vol. 27, no. 12, pp. 1841–1847, 2009. View at Publisher · View at Google Scholar · View at PubMed
  132. S. M. Ngoi, M. G. Tovey, and A. T. Vella, “Targeting poly(I:C) to the TLR3-independent pathway boosts effector CD8 T cell differentiation through IFN-alpha/beta,” Journal of Immunology, vol. 181, no. 11, pp. 7670–7680, 2008. View at Google Scholar
  133. T. Miyake, Y. Kumagai, and Y. Kumagai, “Poly I:C-induced activation of NK cells by CD8 alpha+ dendritic cells via the IPS-1 and TRIF-dependent pathways,” Journal of Immunology, vol. 183, no. 4, pp. 2522–2528, 2009. View at Publisher · View at Google Scholar · View at PubMed
  134. J. Tabiasco, E. Devêvre, N. Rufer, B. Salaun, J.-C. Cerottini, D. Speiser, and P. Romero, “Human effector CD8+ T lymphocytes express TLR3 as a functional coreceptor,” Journal of Immunology, vol. 177, no. 12, pp. 8708–8713, 2006. View at Google Scholar
  135. Y.-F. Lau, L.-H. Tang, and E.-E. Ooi, “A TLR3 ligand that exhibits potent inhibition of influenza virus replication and has strong adjuvant activity has the potential for dual applications in an influenza pandemic,” Vaccine, vol. 27, no. 9, pp. 1354–1364, 2009. View at Publisher · View at Google Scholar · View at PubMed
  136. J. P. Wong, M. E. Christopher, and M. E. Christopher, “Activation of toll-like receptor signaling pathway for protection against influenza virus infection,” Vaccine, vol. 27, no. 25-26, pp. 3481–3483, 2009. View at Publisher · View at Google Scholar · View at PubMed
  137. J. P. Wong, M. E. Christopher, S. Viswanathan, X. Dai, A. M. Salazar, L.-Q. Sun, and M. Wang, “Antiviral role of toll-like receptor-3 agonists against seasonal and avian influenza viruses,” Current Pharmaceutical Design, vol. 15, no. 11, pp. 1269–1274, 2009. View at Publisher · View at Google Scholar
  138. E. Shen, L. Li, L. Feng, L. Lu, Z. Yao, H. Lin, and C. Wu, “PIKA as an adjuvant enhances specific humoral and cellular immune responses following the vaccination of mice with HBsAg plus PIKA,” Cellular & Molecular Immunology, vol. 4, no. 2, pp. 113–120, 2007. View at Google Scholar
  139. C. Trumpfheller, M. Caskey, and M. Caskey, “The microbial mimic poly IC induces durable and protective CD4+ T cell immunity together with a dendritic cell targeted vaccine,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 7, pp. 2574–2579, 2008. View at Publisher · View at Google Scholar · View at PubMed
  140. H. Navabi, B. Jasani, and B. Jasani, “A clinical grade poly I:C-analogue (Ampligen) promotes optimal DC maturation and Th1-type T cell responses of healthy donors and cancer patients in vitro,” Vaccine, vol. 27, no. 1, pp. 107–115, 2009. View at Publisher · View at Google Scholar · View at PubMed
  141. T. Ichinohe, A. Ainai, M. Tashiro, T. Sata, and H. Hasegawa, “PolyI:polyC12U adjuvant-combined intranasal vaccine protects mice against highly pathogenic H5N1 influenza virus variants,” Vaccine, vol. 27, no. 45, pp. 6276–6279, 2009. View at Publisher · View at Google Scholar · View at PubMed
  142. Z. Cui and F. Qiu, “CD4+ T helper cell response is required for memory in CD8+ T lymphocytes induced by a poly(I:C)-adjuvanted MHC I-restricted peptide epitope,” Journal of Immunotherapy, vol. 30, no. 2, pp. 180–189, 2007. View at Publisher · View at Google Scholar · View at PubMed
  143. A. K. Field, A. A. Tytell, G. P. Lampson, and M. R. Hilleman, “Inducers of interferon and host resistance. II. Multistranded synthetic polynucleotide complexes,” Proceedings of the National Academy of Sciences of the United States of America, vol. 58, no. 3, pp. 1004–1010, 1967. View at Google Scholar
  144. G. P. Lampson, A. A. Tytell, A. K. Field, M. M. Nemes, and M. R. Hilleman, “Inducers of interferon and host resistance. I. Double-stranded RNA from extracts of Penicillium funiculosum,” Proceedings of the National Academy of Sciences of the United States of America, vol. 58, no. 2, pp. 782–789, 1967. View at Google Scholar
  145. L. Alexopoulou, A. C. Holt, R. Medzhitov, and R. A. Flavell, “Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3,” Nature, vol. 413, no. 6857, pp. 732–738, 2001. View at Publisher · View at Google Scholar · View at PubMed
  146. H. Kato, O. Takeuchi, and O. Takeuchi, “Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses,” Nature, vol. 441, no. 1, pp. 101–105, 2006. View at Publisher · View at Google Scholar · View at PubMed
  147. E. De Clercq, “Antiviral drug discovery: ten more compounds, and ten more stories (Part B),” Medicinal Research Reviews, vol. 29, no. 4, pp. 571–610, 2009. View at Publisher · View at Google Scholar · View at PubMed
  148. M. Absher and W. R. Stinebring, “Toxic properties of a synthetic double-stranded rna: endotoxin-like properties of poly I.Poly C, an interferon stimulator,” Nature, vol. 223, no. 5207, pp. 715–717, 1969. View at Publisher · View at Google Scholar
  149. R. A. Robinson, V. T. DeVita, H. B. Levy, S. Baron, S. P. Hubbard, and A. S. Levine, “A phase I-II trial of multiple-dose polyriboinosic-polyribocytidylic acid in patieonts with leukemia or solid tumors,” Journal of the National Cancer Institute, vol. 57, no. 3, pp. 599–602, 1976. View at Google Scholar
  150. W. A. Carter, P. M. Pitha, L. W. Marshall, I. Tazawa, S. Tazawa, and P. O. P. Ts'O, “Structural requirements of the rIn·rCn complex for Induction of human interferon,” Journal of Molecular Biology, vol. 70, no. 3, pp. 567–587, 1972. View at Google Scholar
  151. D. R. Strayer, W. A. Carter, and W. A. Carter, “A controlled clinical trial with a specifically configured RNA drug, poly(I) · poly(C12U), in chronic fatigue syndrome,” Clinical Infectious Diseases, vol. 18, supplement 1, pp. S88–S95, 1994. View at Google Scholar
  152. W. A. Carter, D. R. Strayer, and I. Brodsky, “Clinical, immunological, and virological effects of ampligen, a mismatched double-stranded RNA, in patients with AIDS or AIDS-related complex,” Lancet, vol. 1, no. 8545, pp. 1286–1292, 1987. View at Google Scholar
  153. H. B. Levy, G. Baer, and S. Baron, “A modified polyriboinosinic polyribocytidylic acid complex that induces interferon in primates,” Journal of Infectious Diseases, vol. 132, no. 4, pp. 434–439, 1975. View at Google Scholar
  154. A. S. Levine and H. B. Levy, “Phase I-II trials of poly IC stabilized with poly-L-lysine,” Cancer Treatment Reports, vol. 62, no. 11, pp. 1907–1912, 1978. View at Google Scholar
  155. H. X. Lin, C. Gontier, M.-F. Saron, and P. Perrin, “A new immunostimulatory complex (PICKCa) in experimental rabies: antiviral and adjuvant effects,” Archives of Virology, vol. 131, no. 3-4, pp. 307–319, 1993. View at Publisher · View at Google Scholar
  156. B. B. Gowen, M.-H. Wong, and M.-H. Wong, “TLR3 is essential for the induction of protective immunity against Punta Toro virus infection by the double-stranded RNA (dsRNA), poly(I:C 12U), but not poly(I:C): differential recognition of synthetic dsRNA molecules,” Journal of Immunology, vol. 178, no. 8, pp. 5200–5208, 2007. View at Google Scholar
  157. D. Chaudhuri, R. Suriano, A. Mittelman, and R. K. Tiwari, “Targeting the immune system in cancer,” Current Pharmaceutical Biotechnology, vol. 10, no. 2, pp. 166–184, 2009. View at Publisher · View at Google Scholar
  158. R.-F. Wang, Y. Miyahara, and H. Y. Wang, “Toll-like receptors and immune regulation: implications for cancer therapy,” Oncogene, vol. 27, no. 2, pp. 181–189, 2008. View at Publisher · View at Google Scholar · View at PubMed
  159. J. Galon, A. Costes, and A. Costes, “Type, density, and location of immune cells within human colorectal tumors predict clinical outcome,” Science, vol. 313, no. 5795, pp. 1960–1964, 2006. View at Publisher · View at Google Scholar · View at PubMed
  160. S. Ogino, K. Nosho, and K. Nosho, “Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype,” Clinical Cancer Research, vol. 15, no. 20, pp. 6412–6420, 2009. View at Publisher · View at Google Scholar · View at PubMed
  161. L. Laghi, P. Bianchi, and P. Bianchi, “CD3+ cells at the invasive margin of deeply invading (pT3-T4) colorectal cancer and risk of post-surgical metastasis: a longitudinal study,” The Lancet Oncology, vol. 10, no. 9, pp. 877–884, 2009. View at Publisher · View at Google Scholar
  162. FDA, “Approval Letter—Provenge, April 2010 ”, http://www.fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/ucm210215.htm.
  163. P. H. Patel and D. R. Kockler, “Sipuleucel-T: a vaccine for metastatic, asymptomatic, androgen-independent prostate cancer,” Annals of Pharmacotherapy, vol. 42, no. 1, pp. 91–98, 2008. View at Publisher · View at Google Scholar · View at PubMed
  164. C. S. Higano, P. F. Schellhammer, and P. F. Schellhammer, “Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer,” Cancer, vol. 115, no. 16, pp. 3670–3679, 2009. View at Publisher · View at Google Scholar · View at PubMed
  165. E. J. Ilett, R. J. Prestwich, and A. A. Melcher, “The evolving role of dendritic cells in cancer therapy,” Expert Opinion on Biological Therapy, vol. 10, no. 3, pp. 369–379, 2010. View at Google Scholar
  166. L. G. Durrant, V. Pudney, I. Spendlove, and R. L. Metheringham, “Vaccines as early therapeutic interventions for cancer therapy: neutralising the immunosuppressive tumour environment and increasing T cell avidity may lead to improved responses,” Expert Opinion on Biological Therapy, vol. 10, no. 5, pp. 735–748, 2010. View at Google Scholar
  167. A. Makkouk and A. M. Abdelnoor, “The potential use of toll-like receptor (TLR) agonists and antagonists as prophylactic and/or therapeutic agents,” Immunopharmacology and Immunotoxicology, vol. 31, no. 3, pp. 331–338, 2009. View at Publisher · View at Google Scholar · View at PubMed
  168. B. Salaun, I. Coste, M.-C. Rissoan, S. J. Lebecque, and T. Renno, “TLR3 can directly trigger apoptosis in human cancer cells,” Journal of Immunology, vol. 176, no. 8, pp. 4894–4901, 2006. View at Google Scholar
  169. T. Matijevic, M. Marjanovic, and J. Pavelic, “Functionally active toll-like receptor 3 on human primary and metastatic cancer cells,” Scandinavian Journal of Immunology, vol. 70, no. 1, pp. 18–24, 2009. View at Publisher · View at Google Scholar · View at PubMed
  170. A. Paone, D. Starace, R. Galli et al., “Toll-like receptor 3 triggers apoptosis of human prostate cancer cells through a PKC-alpha-dependent mechanism,” Carcinogenesis, vol. 29, no. 7, pp. 1334–1342, 2008. View at Google Scholar
  171. K. Yoneda, K. Sugimoto, and K. Sugimoto, “Dual topology of functional Toll-like receptor 3 expression in human hepatocellular carcinoma: differential signaling mechanisms of TLR3-induced NF-κB activation and apoptosis,” International Journal of Oncology, vol. 33, no. 5, pp. 929–936, 2008. View at Publisher · View at Google Scholar
  172. B. Salaun, S. Lebecque, S. Matikainen, D. Rimoldi, and P. Romero, “Toll-like receptor 3 expressed by melanoma cells as a target for therapy?” Clinical Cancer Research, vol. 13, no. 15, pp. 4565–4574, 2007. View at Publisher · View at Google Scholar · View at PubMed
  173. M. Zhou, M. M. McFarland-Mancini, H. M. Funk, N. Husseinzadeh, T. Mounajjed, and A. F. Drew, “Toll-like receptor expression in normal ovary and ovarian tumors,” Cancer Immunology, Immunotherapy, vol. 58, no. 9, pp. 1375–1385, 2009. View at Publisher · View at Google Scholar · View at PubMed
  174. B. Jasani, H. Navabi, and M. Adams, “Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer,” Vaccine, vol. 27, no. 25-26, pp. 3401–3404, 2009. View at Publisher · View at Google Scholar · View at PubMed
  175. H. B. Levy, “Historical overview of the use of polynucleotides in cancer,” Journal of Biological Response Modifiers, vol. 4, no. 5, pp. 475–480, 1985. View at Google Scholar
  176. N. Butowski, S. M. Chang, and S. M. Chang, “A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05),” Journal of Neuro-Oncology, vol. 91, no. 2, pp. 175–182, 2009. View at Publisher · View at Google Scholar · View at PubMed
  177. N. Butowski, K. R. Lamborn, and K. R. Lamborn, “A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas,” Journal of Neuro-Oncology, vol. 91, no. 2, pp. 183–189, 2009. View at Publisher · View at Google Scholar · View at PubMed
  178. A. S. Levine, M. Sivulich, P. H. Wiernik, and H. B. Levy, “Initial clinical trials in cancer patients of polyriboinosinic-polyribocytidylic acid stabilized with poly-L-lysine, in carboxymethylcellulose [poly(ICLC)], a highly effective interferon inducer,” Cancer Research, vol. 39, no. 5, pp. 1645–1650, 1979. View at Google Scholar
  179. C. H. Ewel, W. J. Urba, and W. J. Urba, “Polyinosinic-polycytidylic acid complexed with poly-L-lysine and carboxymethylcellulose in combination with interleukin 2 in patients with cancer: clinical and immunological effects,” Cancer Research, vol. 52, no. 11, pp. 3005–3010, 1992. View at Google Scholar
  180. B. J. Giantonio, H. Hochster, and H. Hochster, “Toxicity and response evaluation of the interferon inducer poly ICLC administered at low dose in advanced renal carcinoma and relapsed or refractory lymphoma: a report of two clinical trials of the eastern cooperative oncology group,” Investigational New Drugs, vol. 19, no. 1, pp. 89–92, 2001. View at Publisher · View at Google Scholar
  181. A. E. Maluish, J. W. Reid, and E. A. Crisp, “Immunomodulatory effects of poly(I,C)-LC in cancer patients,” Journal of Biological Response Modifiers, vol. 4, no. 6, pp. 656–663, 1985. View at Google Scholar
  182. X. Zhu, F. Nishimura, and F. Nishimura, “Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models,” Journal of Translational Medicine, vol. 5, article 10, 2007. View at Publisher · View at Google Scholar · View at PubMed
  183. H. Okada, “Brain tumor immunotherapy with type-1 polarizing strategies,” Annals of the New York Academy of Sciences, vol. 1174, pp. 18–23, 2009. View at Publisher · View at Google Scholar · View at PubMed
  184. H. C. Jeung, Y. W. Moon, and S. Y. Rha, “Phase III trial of adjuvant 5-fluorouracil and adriamycin versus 5-fluorouracil, adriamycin, and polyadenylic-polyuridylic acid (poly A:U) for locally advanced gastric cancer after curative surgery: final results of 15-year follow-up,” Annals of Oncology, vol. 19, no. 3, pp. 520–526, 2008. View at Google Scholar
  185. J. Lacour, A. Laplanche, and A. Laplanche, “Polyadenylic-polyuridylic acid as an adjuvant in resectable colorectal carcinoma: a 6 1/2 year follow-up analysis of a multicentric double blind randomized trial,” European Journal of Surgical Oncology, vol. 18, no. 6, pp. 599–604, 1992. View at Google Scholar
  186. L. Wang, D. Smith, S. Bot, L. Dellamary, A. Bloom, and A. Bot, “Noncoding RNA danger motifs bridge innate and adaptive immunity and are potent adjuvants for vaccination,” Journal of Clinical Investigation, vol. 110, no. 8, pp. 1175–1184, 2002. View at Publisher · View at Google Scholar
  187. A. Bot, D. Smith, B. Phillips, S. Bot, C. Bona, and H. Zaghouani, “Immunologic control of tumors by in vivo Fc gamma receptor-targeted antigen loading in conjunction with double-stranded RNA-mediated immune modulation,” Journal of Immunology, vol. 176, no. 3, pp. 1363–1374, 2006. View at Google Scholar
  188. T. Sugiyama, K. Hoshino, and K. Hoshino, “Immunoadjuvant effects of polyadenylic: polyuridylic acids through TLR3 and TLR7,” International Immunology, vol. 20, no. 1, pp. 1–9, 2008. View at Publisher · View at Google Scholar · View at PubMed
  189. B. Huang, J. Zhao, J. C. Unkeless, Z. H. Feng, and H. Xiong, “TLR signaling by tumor and immune cells: a double-edged sword,” Oncogene, vol. 27, no. 2, pp. 218–224, 2008. View at Publisher · View at Google Scholar · View at PubMed
  190. R. Chen, A. B. Alvero, D.-A. Silasi, K. D. Steffensen, and G. Mor, “Cancers take their Toll—the function and regulation of Toll-like receptors in cancer cells,” Oncogene, vol. 27, no. 2, pp. 225–233, 2008. View at Publisher · View at Google Scholar · View at PubMed
  191. M. Lehoux, C. M. D'Abramo, and J. Archambault, “Molecular mechanisms of human papillomavirus-induced carcinogenesis,” Public Health Genomics, vol. 12, no. 5-6, pp. 268–280, 2009. View at Publisher · View at Google Scholar · View at PubMed
  192. F. H. Pujol, M.-C. Navas, P. Hainaut, and I. Chemin, “Worldwide genetic diversity of HBV genotypes and risk of hepatocellular carcinoma,” Cancer Letters, vol. 286, no. 1, pp. 80–88, 2009. View at Publisher · View at Google Scholar · View at PubMed
  193. E. L. Franco, F. Coutlée, and A. Ferenczy, “Integrating human papillomavirus vaccination in cervical cancer control programmes,” Public Health Genomics, vol. 12, no. 5-6, pp. 352–361, 2009. View at Publisher · View at Google Scholar · View at PubMed
  194. S. G. Lim, R. Mohammed, M.-F. Yuen, and J.-H. Kao, “Prevention of hepatocellular carcinoma in hepatitis B virus infection,” Journal of Gastroenterology and Hepatology, vol. 24, no. 8, pp. 1352–1357, 2009. View at Publisher · View at Google Scholar · View at PubMed
  195. A. Plymoth, S. Viviani, and P. Hainaut, “Control of hepatocellular carcinoma through Hepatitis B vaccination in areas of high endemicity: perspectives for global liver cancer prevention,” Cancer Letters, vol. 286, no. 1, pp. 15–21, 2009. View at Publisher · View at Google Scholar · View at PubMed
  196. A. H. Sherker, “ACP Journal Club. Review: interferon and nucleoside/tide analogues reduce risk for hepatocellular cancer in patients with chronic hepatitis B,” Annals of Internal Medicine, vol. 150, no. 8, pp. 4–11, 2009. View at Google Scholar
  197. W. P. Drake, W. J. Pendergrast Jr., and M. R. Mardiney Jr., “Enhancement of spontaneous C3H/HeJ mammary tumorigenesis by long term polyadenylic polyuridylic acid therapy,” Cancer Research, vol. 35, no. 11 I, pp. 3051–3053, 1975. View at Google Scholar
  198. F. Stenback, G. Curtis, and W. Ryan, “Polyadenylate-polyuridylate enhancement of 7,12-dimethylbenz-anthracene skin carcinogenesis,” Experientia, vol. 35, no. 9, pp. 1232–1233, 1979. View at Google Scholar
  199. H. Liu, M. Komai-Koma, D. Xu, and F. Y. Liew, “Toll-like receptor 2 signaling modulates the functions of CD4+ CD25+ regulatory T cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 18, pp. 7048–7053, 2006. View at Publisher · View at Google Scholar · View at PubMed
  200. R. P. M. Sutmuller, M. H. M. G. M. Den Brok, and M. H. M. G. M. Den Brok, “Toll-like receptor 2 controls expansion and function of regulatory T cells,” Journal of Clinical Investigation, vol. 116, no. 2, pp. 485–494, 2006. View at Publisher · View at Google Scholar · View at PubMed
  201. E. M. El-Omar, M. T. Ng, and G. L. Hold, “Polymorphisms in Toll-like receptor genes and risk of cancer,” Oncogene, vol. 27, no. 2, pp. 244–252, 2008. View at Publisher · View at Google Scholar · View at PubMed
  202. M. Fukata and M. T. Abreu, “Role of Toll-like receptors in gastrointestinal malignancies,” Oncogene, vol. 27, no. 2, pp. 234–243, 2008. View at Publisher · View at Google Scholar · View at PubMed
  203. U. K. Scarlett, J. R. Cubillos-Ruiz, and J. R. Cubillos-Ruiz, “In situ stimulation of CD40 and toll-like receptor 3 transforms ovarian cancer-infiltrating dendritic cells from immunosuppressive to immunostimulatory cells,” Cancer Research, vol. 69, no. 18, pp. 7329–7337, 2009. View at Publisher · View at Google Scholar · View at PubMed
  204. Y. Zhang, R. Sun, and R. Sun, “TLR3 activation inhibits nasopharyngeal carcinoma metastasis via downregulation of chemokine receptor CXCR4,” Cancer Biology and Therapy, vol. 8, no. 19, pp. 1826–1830, 2010. View at Google Scholar
  205. K. Karikó, H. Ni, J. Capodici, M. Lamphier, and D. Weissman, “mRNA is an endogenous ligand for Toll-like receptor 3,” Journal of Biological Chemistry, vol. 279, no. 13, pp. 12542–12550, 2004. View at Publisher · View at Google Scholar · View at PubMed
  206. J. Andrejeva, K. S. Childs, D. F. Young, T. S. Carlos, N. Stock, S. Goodbourn, and R. E. Randall, “The V proteins of paramyxoviruses bind the IFN-inducible RNA helicase, mda-5, and inhibit its activation of the IFN-β promoter,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 49, pp. 17264–17269, 2004. View at Publisher · View at Google Scholar · View at PubMed
  207. P. M. Barral, D. Sarkar, P. B. Fisher, and V. R. Racaniello, “RIG-I is cleaved during picornavirus infection,” Virology, vol. 391, no. 2, pp. 171–176, 2009. View at Publisher · View at Google Scholar · View at PubMed
  208. A. Arjona, M. Ledizet, K. Anthony, N. Bonafé, Y. Modis, T. Town, and E. Fikrig, “West Nile virus envelope protein inhibits dsRNA-induced innate immune responses,” Journal of Immunology, vol. 179, no. 12, pp. 8403–8409, 2007. View at Google Scholar
  209. D. Alonso-Curbelo and M. S. Soengas, “Self-killing of melanoma cells by cytosolic delivery of dsRNA: wiring innate immunity for a coordinated mobilization of endosomes, autophagosomes and the apoptotic machinery in tumor cells,” Autophagy, vol. 6, no. 1, pp. 148–150, 2010. View at Google Scholar